Evidence for Clinical Safety, Efficacy, and Parent and Physician Perceptions of Levocetirizine for the Treatment of Children with Allergic Disease

Explore this paper's citation graph

Summary

Levocetirizine is the only H1-antihistamine launched in the 21st century shown to lack clinically relevant adverse effects on physical and psychomotor development or routine laboratory tests over a long-term period of 18 months in 1- to 3-year-old children predisposed to development of allergic disease.

Type
article
Published
2011-02-22
Cited by
37
References
77

Keywords

Economics, Political science

References

Cited by

Related papers

No related papers recorded.